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Purpose: To compare the incidence and magnitude of weight gain associated with
valproic acid (VPA) monotherapy in male and female epilepsy patients and to
determine possible gender-specific differences in frequency of carbohydrate craving,
body-composition, glucose homeostasis and lipid metabolism.
Methods: Epilepsy patients on VPA monotherapy were consecutively recruited at the
outpatient clinic of the Department of Neurology, Innsbruck Medical University.
Weight gain during VPA-therapy, frequency of carbohydrate craving and physical
exercise, sociopsychological problems and family history for diabetes were obtained
from all patients. Clinical data also comprised body-impedance analysis, body mass
index and waist-to-hip ratio. Morning fasting blood samples were drawn to determine
serum leptin, glucose and lipid concentrations, as well as insulin, C-reactive protein
and TNF-a.
Results: One hundred and six patients (55 women) were enrolled in the study.
Significant weight gain was seen during VPA-therapy in both genders (each
p < 0.001) with women experiencing increment of weight more frequently and more
pronounced than did men. Analyses of patients who gained weight during VPA-therapy
revealed significantly higher serum leptin concentrations in women than in men
( p < 0.001). Women also revealed significantly higher high-density lipoprotein-cho-
lesterol and lower triglyceride concentrations than men ( p = 0.004 and 0.014,
respectively). Frequency of carbohydrate craving was 25.8% in women and 14.3%
in men. More women tried to lose or control weight through diet than did men (22.6%
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Valproate and weight gain 227versus 7.1%). Moreover, weight gain as a sociopsychological problem was more
numorous in women than in men.
Conclusion: Women are more prone to gain weight during VPA therapy though higher
frequency of diet and sociopsychological burden than men, which might possibly be
related to leptin-resitance and a higher frequency of carbohydrate craving.
# 2006 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Valproic acid (VPA) has a broad spectrum of antic-
onvulsant activity, being at present the antiepilep-
tic drug (AED) of choice for all forms of generalized
epilepsy and has become established worldwide as
one of the most widely prescribed AEDs.1,2 However,
weight gain as the most common side-effect of
VPA3—5 limits its use in clinical practice more often
than do other possible idiosyncratic side-effects and
high rates of teratogenicity. VPA-related weight gain
was found to be frequent in women with epilepsy,
increasing the possibility for metabolic distur-
bances.4 Verrotti et al. reported the development
of obesity in 37% of female patients with epilepsy
after 1 year of treatment with VPA.6 Weight gain due
to VPA treatment is usually observed during the first
3months of therapy,7—11 reaching its maximum after
6 months.3,4,12,13
Consequences of VPA-associated weight gain are
the risk for developing non-alcoholic fatty liver
disease (NAFLD)14 and insulin resistance (IR).4,15,16
Furthermore, it is well established that weight gain
and obesity are associated with an increase in
patients’ cardiovascular risk17 and increased non-
compliance or therapy interruption.12,13,18
Up to now, attempts to determine factors respon-
sible for VPA-induced weight gain failed.19 Several
mechanisms have been proposed: (i) ineffective
leptin action despite high leptin levels,6,20,21 (ii)
hyperinsulinemia resulting from increased secretion
of b-cells22 and (iii) increased consumption of food
and energy-rich drinks due to increased appetite
(e.g. carbohydrate craving) and modified thirst.3,13
VPA treatment in humans is known to increase the
serum level of two hormones, leptin6,20,21 and insu-
lin,23 produced by adipose tissue and the pancreatic
islet cells,22 respectively. One of the physiologic
roles of leptin is an appetite-reducing feedback
signal.24 In humans, serum leptin and insulin con-
centrations are associated with the amount of adi-
pose tissue and are higher in obese than in lean
people.25,26 In epilepsy patients, higher serum lep-
tin as well as insulin concentrations in overweight
females compared to males15 have been demon-
strated.
To date, the etiology of VPA-induced weight gain
is considered to be multi-factorial since weight isthe output of energy homeostasis controlled by
many organs that produce and secrete a variety
of appetite-regulating peptides and cytokines that
act within the hypothalamus.27
The aims of this study were to elucidate possible
effects of gender on the magnitude of VPA-asso-
ciated weight gain, carbohydrate craving and dis-
turbances in body-composition, glucose and lipid
homeostasis.Methods
One hundred and twenty patients (61 women and 59
age matched men) were consecutively recruited
from our outpatient clinic, presenting with either
partial or generalized epilepsy treated with VPA
monotherapy for at least 6 months. None of the
patients had any other regular medication in addi-
tion to VPA. Patients with a mental handicap, with a
history of psychogenic seizures and/or concomitant
diseases possibly contributing to weight gain were
excluded.
All patients underwent standardized question-
naire about family history of diabetes, the magni-
tude of weight gain under VPA therapy, eating
habits, especially carbohydrate craving, sociopsy-
chological burden of weight gain and physical exer-
cise at the time of investigation. Each patient was
measured for weight, height, hips and waist using a
wall-mounted stadiometer, a tape measure and a
calibrated weight scale, respectively, with subjects
wearing underwear only.
Body-impedance analysis and fasting blood sam-
ples were obtained in all patients fulfilling the
inclusion criteria between 8 and 10 in the morning.
Each sample of whole blood was centrifuged to
obtain serum, which was immediately frozen at
80 8C within 1 h after sampling, and stored in
aliquots until the assays were run. Additionally,
baseline anthropometric data from 1 day before
VPA treatment was obtained from the patients’
record (‘‘initial weight’’).
Body impedance as an expression of body fat
portion was measured with a body fat monitor
(OMRON BF 302), which measures the percentage
and total amount of fat in kilograms contained in the
human body. It analyses the electrical resistance of
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through the upper body.28 Body fat was classified in
categories according to Deurenberg et al.29 as thin,
normal, stout, obese and extremely obese in men/
women (<10/<20%), (10—20/20—30%), (20—25/
30—35%), (25—30/35—40%), (>30/>40%).
Glucose was measured with an automated hex-
okinase method (HK, Uni-Kit III, Roche, Basle, Swit-
zerland; RIA-mat, C-peptide II, Byk-Sangtec
Diagnostica, Germany). Serum free insulin and C-
peptide were determined with radioimmunoassay
(RIA, Pharmacia, Uppsala), and proinsulin with an
enzyme immunoassay (Mercodia, Uppsala, Sweden).
High-sensitive C-reactive protein was determined
with use of the CRP (Latex) ultrasensitive assay
(Roche, Vienna, Austria). Tumor-necrosis-factor-
alpha was measured with TNF-a EASIA (Biosource,
Belgium).
Plasma leptin concentrations were measured
with an enzyme-linked immunosorbent assay (R&D
System, Wiesbaden, Germany).
The homeostasis model assessment (HOMA) index
for insulin resistance (HOMA-IR) as a measure for
insulin resistance was calculated as fasting glucose
(mmol/l)  fasting serum insulin (mU/ml)/22.5.
Plasma lipids, thyroid, liver and kidney function
test were determined according to routine proce-
dures.
Statistical analysiswas performed using SPSS soft-
ware; p values less than 0.05 were considered sig-
nificant. Items used include the Chi-square test, T-
test, Pearson and Spearman correlation coefficient.Results
All of 120 patients agreed to participate in the study
and attended the interview. Six patients did notTable 1 Baseline characteristics and anthropometric data
Wom
Age (years) 34
Seizure type distribution (%)
Generalized 84
Partial 18
Duration of treatment (years) 1.5
VPA dosage (mg/day) 1141
VPA serum level (mg/ml) 50.4
Height (m) 1.65
Initial weight (kg) 62.5
Follow up weight (kg) 67.5
Initial BMI 22.8
Follow up BMI 24.7
Weight gain during valproate treatment (%) 56.4
n, number of subjects; values are absolute numbers and percentag
a p < 0.001 when compared with initial weight or BMI.attend blood sampling session, eight patients’ initial
weight was not documented. Therefore, 106
patients (55 women and 51 age-matched men;
Table 1) were included in our study. Baseline char-
acteristics andmain results are presented in Table 1.
The mean duration of VPA treatment was
1.5  0.7 years in women and 1.8  0.5 years in
men, demonstrating no significant difference
(p = 0.530). VPA dosages were similar in both
groups, no significant difference in seizure type
distribution was seen between genders (Table 1).
Significant weight gain was seen during VPA-therapy
in both genders (each p < 0.001) with women
experiencing increment of weight more frequently
and more pronounced than did men (Tables 1 and 2).
A high portion of patients in both genders who
gained weight during VPA-therapy faced significant
weight gain of>5 kg (Table 2). Althoughmean BMI at
baseline was significantly different between women
and men ( p = 0.031), an almost identical mean BMI
was seen at follow up ( p = 0.659; Table 1). Percen-
tage of body fat and waist-to-hip ratio differed
statistically between genders with women having
higher percentage of body fat and a lower waist/hip
ratio (27.5  6.9% versus 18.7  7.1% and 0.79 
0.05 versus 0.91  0.07, respectively). Serum leptin
concentration was significantly higher in women
than in men (18.0  12.5 ng/ml versus 5.0 
4.1 ng/ml, p < 0.001). Women also revealed signif-
icantly higher HDL-cholesterol concentrations than
men (62.5  17.4 mg/dl versus 48.8  11.7 mg/dl,
p < 0.001). Parameters of glucose homeostasis and
inflammation did not reveal any differences.
Additional analyses were performed in patients
who gained weight during VPA-therapy.
Comparison of women and men who gained
weight during VPA-therapy showed statistically
different waist-to-hip ratio and percentage of bodyof the study population
en (n = 55) Men (n = 51) p-Value
 10 35  13 0.577
71
39
 0.7 1.8  0.5 0.530
 498 1255  526 0.381
 22.7 55.8  25.2 0.144
 0.06 1.79  0.09 <0.001
 10.2 77.7  13.8 <0.001
 10.0a 79.9  14.2a <0.001
 3.4 24.3  3.5 0.031
 3.6a 25.0  3.7a 0.659
27.5
e or means  S.D. BMI, body-mass index.
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Table 2 Anthropometric data and other information of subjects who gained weight under VPA
Women (n = 31) Men (n = 14) p-Value
Average weight gain (kg) 8.8  7.0 7.9  4.4 0.949
Significant weight gain (5 kg; %) 43.6 23.5
Average significant weight gain (kg) 13.4  7.1 10.5  4.0 0.299
Carbohydrage craving attacks (%) 25.8 14.3
Dietary regimens (%) 22.6 7.1
Physical activity (%) 64.5 37.5
Family history of diabetes (%) 34.5 21.4
Initial BMI 22.9  4.0 24.7  3.7 0.156
Follow-up BMI 26.1  3.5a 27.2  3.6a 0.361
Waist/hip ratio average 0.79  0.05 0.93  0.05 <0.001
Waist/hip ratio 6.4% (>0.85) 7.1% (>1)
Body fat (% of body weight) 22.5% (>35%) 21.4% (>25%)
Body fat average (%) 29.8  6.7 21.1  6.5 <0.001
Weight gain as a sociopsychological problem (%) 54.8 21.4
n, number of subjects; values are absolute numbers and percentage or means  S.D. BMI, body-mass index.
a p < 0.001 when compared with initial BMI.fat between men and women, with women expres-
sing higher percentage of body fat and a lower
waist/hip ratio (Table 2).
Frequency of carbohydrate craving was 25.8% in
women and 14.3% in men. Reported sport activities
did not differ between both genders. However, more
women than men tried to lose or control weight by
diet (22.6% versus 7.1%). Moreover, weight gain as a
sociopsychological problemwasmore pronounced in
women than in men (54.8% versus 21.4%). There was
no difference in the frequency of diabetes in
families of men or women (Table 2).
Serum leptin concentration was significantly
higher in women than inmen (p < 0.001) who gained
weight during VPA-therapy. Women also revealed
significantly higher HDL-cholesterol concentrations
and lower triglyceride concentrations than men
(p = 0.004 and 0.014, respectively; Table 3).Table 3 Metabolic and inflammatory parameters of patien
Wome
Leptin (ng/ml) 23.1
Fasting insulin (mU/ml) 12.2
Proinsulin (pmol/l) 15.5
C-peptide (pmol/ml) 0.73
Fasting glucose (mg/dl) 74.8
HOMA index 2.4
HbA1c (%) 5.4




Lipoprotein (a) (mg/dl) 29.2
TNF-a (pg/ml) 19.7
High-sensitive C-reactive protein (mg/dl) 0.35
n, number of subjects; values are absolute numbers and percentag
index for insulin resistance; TNF-a, tumor-necrosis-factor alpha; LFasting plasma glucose, insulin, pro-insulin and C-
peptide as well as the HOMA-IR did not differ sig-
nificantly between men and women (Table 3). Inter-
estingly, two parameters associated with the
inflammatory aspect of obesity, namely TNF-a and
CRP, did not show any statistical difference between
genders (Table 3).Discussion
The present study demonstrates a more pro-
nounced and more frequent weight gain in women
receiving VPA monotherapy compared to men. VPA
treatment was associated with various degrees
of weight gain (mild, moderate or excessive) for
both genders, with incidences comparable to
prior studies.7,11,30—32ts who gained weight under VPA
n (n = 31) Men (n = 14) p-Value
 13.1 6.7  3.3 <0.001
 11.7 15.2  12.4 0.444
 24.2 31.7  60.2 0.208
 0.33 0.95  0.46 0.080
 24.5 89.4  29.3 0.104
 3.3 4.0  4.6 0.189
 0.5 5.5  0.7 0.771
 39.2 209.0  28.5 0.455
 19.4 44.0  10.5 0.004
 38.6 133.8  22.2 0.100
 64.00 195.4  113.3 0.014
 32.1 40.9  37.3 0.315
 20.2 14.0  5.3 0.162
 0.52 0.23  0.33 0.492
e or means  S.D. HOMA index, homeostasis model assessment
DL, low-densitiy lipoprotein; HDL, high-density lipoprotein.
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sumption of food and energy-rich drinks due to
increased appetite (e.g. carbohydrate craving)
and modified thirst,3,13 were proposed to explain
the weight modifying effect of VPA therapy. Carbo-
hydrate craving is a frequently observed phenom-
enon in patients with affective disorders.33—36
However, the proximate mechanisms for increased
intake have not been identified yet. Carbohydrate
craving has been attributed to central serotonine
depletion and is felt to be a macronutrient-specific
appetite.34—36 This is the first study showing carbo-
hydrate craving to be a common side-effect pre-
dominantly in women undergoing VPA-therapy. In
patients undergoing VPA-therapy this might be pos-
sibly related to postprandial insulin secretion
recently described.23 Furthermore, sociopsycholo-
gical burden of women experiencing weight gain
due to VPA therapy is higher compared to man,
resulting in increased non-compliance and ther-
apy-interruption.
Other possibly involved mechanisms in VPA-asso-
ciated weight gain include defective sympathetic
nervous system activity,37 modulation on a genetic
basis for obesity,38 carnitine deficiency causing
impaired beta-oxidation of fatty acids,39 ineffective
leptin action despite high leptin levels (leptin-resis-
tancy)6,20,21 and hyperinsulinemia resulting from
increased secretion of b-cells.22
Beside its function as energy storage, adipose
tissue acts as an endocrine organ by releasing var-
ious factors into the circulation. The so-called adi-
pocytokines (e.g. leptin, adiponectin) have recently
been defined as a link between increased body
weight and the development of insulin resis-
tance.40—42 Leptin is a key homeostatic regulator
of body weight20,21 and energy expenditure.24,43,44
As previously reported, serum leptin levels were
higher in female than in male overweight epilepsy
patients, possibly leading to leptin-resistance.15 In
accordance, women revealed a higher percentage
of body fat paralleled by higher plasma leptin levels
compared to men in this study.
To us, however, this finding by itself does not
account for the higher incidence of weight gain in
women solely. The question whether leptin over-
production is one of the causes or consequences of
obesity has not even settled. The diverse mechan-
isms linking leptin to the brain and peripheral tissues
might clarify the pathogenesis of obesity and asso-
ciated diseases.
Interestingly, female patients showed lower fast-
ing triglycerides and increased HDL-cholesterol
values compared to men, indicating a higher degree
of insulin sensitivity. This might be due to a higher
percentage of women trying to lose weight by diet-ary procedures resulting in a more favourable lipid
composition. Only recently, visceral fat mass has
been found to be a major correlate of diabetogenic,
atherogenic, prothrombotic and proinflammatory
metabolic abnormalities reffered to as the meta-
bolic syndrome.45,46 A moderate weight loss in
abdominally obese patients is associated with sub-
stantial improvements in the metabolic profile.45,46
In this study, waist/hip ratios were different in both
sexes reflecting different physiological and consti-
tutional attributes of men and women. Interest-
ingly, both genders showed a similar rate of
elevated waist/hip ratios, indicating similar meta-
bolic burden through an increase in visceral fat
mass.
Additionally to adipocytokines, adipose tissue
secretes various markers of subclinical inflammation
(e.g. C-reactive protein, TNF-a).47,48 It is well
established, that subclinical inflammation is related
to the development of insulin resistance, type 2
diabetes and increased cardiovascular risk.49—52
Unexpectedly, plasma levels of C-reactive protein
and TNF-a did not differ between lean and over-
weight patients as well as between men and women
who gained weight under VPA treatment.
Long-term VPA treatment and weight gain are
frequently associated with the development of
hyperinsulinemia, suggesting development of insu-
lin resistance.9,15
Some authors suggest an association between
hyperinsulinemia and various endocrine abnormal-
ities, possibly stimulating the ovaries to overpro-
duce androgens causing hirsutism and metabolic
disorders.53,54 In detail, insulin inhibits the produc-
tion of the hepatic synthesis of insulin-like growth
factor 1 binding protein (IGFBP-1), which might lead
to increased bioactive insulin-like growth factor 1
(IGF-1) levels.53 Despite insulin resistance in adipose
and muscular tissue, the ovaries remain insulin
sensitive and as a result, insulin as well as IGF-1
still exerts stimulatory effects on the ovar-
ies.10,53,55,56 These effects include theca cell hyper-
plasia and consequently increased production of
androgens.10,53,55,56 Despite the higher percentage
of weight gain in women, as well as the higher
percentage of body fat paralleled by higher plasma
leptin levels, we could not find significant differ-
ences in serum fasting glucose, serum insulin con-
centrations or HOMA-IR between men and women
undergoing VPA therapy.
Unfortunately, predictors of weight gain due to
VPA therapy have not yet been identified. Contra-
dictory results were reported for variables such as
baseline weight and BMI, gender, valproate dose,
seizure or epilepsy type and neurocognitive sta-
tus.6,39,57 There is, for example, some evidence that
Valproate and weight gain 231weight gain problems are more common in patients
with psychogenic seizures.58 In addition, patients
with generalized versus partial seizures11 and those
with normal versus abnormal neurocognitive sta-
tus58 tend to be at greater risk for an increase in
weight. To rule out conflicting data, no patients with
psychogenic seizures or abnormal neurocognitive
status were included in this study. We did not find
any difference in incidence of weight gain between
generalized and partial epilepsy patients.
In conclusion, our evaluation demonstrates gen-
der disparities in weight modifying effects of
valproate in epilepsy patients. Women are more
prone to gain weight during VPA therapy than
men. This might possibly be related to leptin-resis-
tance or high frequency of carbohydrate craving.
Because sociopsychological burden of women
experiencingweight gain due to VPA therapy is high,
prevention and therapeutic approaches should
focus on women and include strategies against
carbohydrate craving.References
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